Free Trial
→ Elon Social Security shock? (From Altimetry) (Ad)

Marinus Pharmaceuticals Q4 2023 Earnings Report

Marinus Pharmaceuticals logo
$0.55 0.00 (-0.16%)
As of 02/11/2025
Earnings HistoryForecast

Marinus Pharmaceuticals EPS Results

Actual EPS
-$0.74
Consensus EPS
-$0.64
Beat/Miss
Missed by -$0.10
One Year Ago EPS
-$0.76

Marinus Pharmaceuticals Revenue Results

Actual Revenue
$7.19 million
Expected Revenue
$7.78 million
Beat/Miss
Missed by -$590.00 thousand
YoY Revenue Growth
N/A

Marinus Pharmaceuticals Announcement Details

Quarter
Q4 2023
Date
3/5/2024
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Powered by Quartr

Marinus Pharmaceuticals Earnings Headlines

StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)
February 17, 2025 | americanbankingnews.com
Marinus Pharmaceuticals (NASDAQ:MRNS) Acquisition Completed by Immedica Pharma AB
February 13, 2025 | americanbankingnews.com
The FED is losing the war on inflation
It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…
February 22, 2025 | WealthPress (Ad)
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock
February 11, 2025 | msn.com
Marinus Pharmaceuticals director sells shares worth $869
January 24, 2025 | msn.com
Marinus pharmaceuticals director sells shares for $864
January 24, 2025 | msn.com
See More Marinus Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Marinus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Marinus Pharmaceuticals and other key companies, straight to your email.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals (NASDAQ:MRNS), a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

View Marinus Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles